Table 2 Pretreatment HIV drug resistance in studied populations

Total

6.0 (5.1–6.8)

NNRTIs^a

3.3 (2.6–3.9)

E138A/G/K, 60 (1.9)

K103N, 14 (0.4)

V179D/E, 13 (0.4)

V108I, 8 (0.2)

G190A/E, 7 (0.2)

Y181C/I, 7 (0.2)

V106I/M, 6 (0.2)

A98G, 3 (0.1)

Y188L/H, 3 (0.1)

 EFV^d,e

1.3 (0.9–1.7)

 NVP^d,e

1.6 (1.1–2.0)

 ETR^e

0.6 (0.3–0.8)

 RPV^e

2.6 (2.1–3.2)

 DOR

0.6 (0.4–0.9)

NRTIs^b

1.7 (1.2–2.1)

K70E/T, 9 (0.3)

T215S/D/A, 8 (0.2)

V75M/A, 8 (0.2)

T69GNS/D, 7 (0.3)

L74I/V, 6 (0.2)

M184V/I, 4 (0.1)

L210W, 4 (0.1)

M41L, 4 (0.1)

D67N, 3 (0.1)

 ABC^d,e

0.7 (0.4–0.9)

 AZT^d,e

0.6 (0.3–0.8)

 3TC^d,e

0.2 (0.1–0.3)

 TDF^d,e

0.3 (0.1–0.5)

 FTC^d,e

0.2 (0.1-.03)

 D4T^d,e

1.1 (0.8–1.5)

 DDI^d

1.0 (0.7–1.4)

PIs^c

1.2 (0.9–1.6)

M46L/I/V, 20 (0.6)

Q58E, 15 (0.5)

G73S/CFV, 3 (0.1)

L10F, 2 (0.1)

 LPV/r^d,e

0.1 (0–0.2)

 ATV/r^d,e

0.1 (0–0.2)

 DRV/r^d,e

0

 FPV/r

0.1 (0–0.2)

 IDV/r

0.2 (0–0.3)

 NFV/r

0.8 (0.5–1.1)

 SQV/r

0.2 (0–0.3)

 TPV/r

0.5 (0.3–0.7)